what is known already: Although vitrification has been reported to be associated with significantly increased post-thaw survival rates compared with slow freezing, there has been a lack of general consensus over which method of cryopreservation (vitrification versus slow freezing) is most appropriate for blastocysts. study design, size, duration: A population-based cohort of autologous fresh and initiated thaw cycles (a cycle where embryos were thawed with intention to transfer) performed between January 2009 and December 2011 in Australia and New Zealand was evaluated retrospectively. A total of 46 890 fresh blastocyst transfer cycles, 12 852 initiated slow frozen blastocyst thaw cycles and 20 887 initiated vitrified blastocyst warming cycles were included in the data analysis.
Introduction
Embryo cryopreservation is considered a vital part of successful assisted reproduction technology (ART) treatment. Compared with the traditional slow freezing method, embryo vitrification is a recently introduced ultrarapid cryopreservation method that prevents ice formation within the suspension which is converted to a glasslike solid, avoiding damage to the cells or tissues (Liebermann and Tucker, 2006; Son and Tan, 2009; Zegers-Hochschild et al., 2009) . Vitrification is relatively simple, inexpensive and potentially faster as the ultrarapid cooling technique requires no expensive programmable controlled-rate freezing equipment (Loutradi et al., 2008; Youssry et al., 2008) . Embryo vitrification was first introduced clinically in Australia in 2006 and is now used for almost three-quarters of autologous thaw cycles where a blastocyst is transferred (Costigan et al., 2007; Macaldowie et al., 2013) .
Vitrification was reported to be associated with significantly increased post-thaw survival rate compared with slow freezing in two literature reviews and meta-analyses. Loutradi et al. found that survival rates of blastocysts were significantly higher after vitrification compared with slow freezing (odds ratio (OR): 2.20, 95% confidence interval (CI): 1.53 -3.16) (Loutradi et al., 2008) . Similarly, Kolibianakis and colleagues reported better post-thaw survival rates for embryos vitrified at the blastocyst stage compared with slow freezing (OR: 4.09, 95% CI: 2.45 -6.84) (Kolibianakis et al., 2009) . However, although post-thaw survival rate is an important end-point when evaluating the efficacy of vitrification versus slow freezing, ultimately the success of ART treatment should be defined by live delivery rate (Edgar and Gook, 2012) .
The recent UK Association of Clinical Embryologists consensus meeting reported that there was lack of consensus over which method of cryopreservation (vitrification versus slow freezing) is most appropriate for cleavage stage embryos and blastocysts (Brison et al., 2012) . A systematic review and meta-analysis of controlled clinical trials suggested there was a significantly higher clinical pregnancy rate and ongoing pregnancy rate with vitrification compared with slow freezing (OR: 1.55, 95% CI: 1.03-2.32, OR: 1.82, 95% CI: 1.04-3.20, respectively), but no statistically significant difference in live birth rate was found (AbdelHafez et al., 2010) . Another systematic review and meta-analysis could not detect significant difference in clinical pregnancy rates per transfer between the vitrification and slow freezing cryopreservation methods (Kolibianakis et al., 2009) .
The need for follow-up studies on babies born after vitrification of blastocysts was highlighted due to concerns about the potential cytotoxicity related to high concentrations of cryoprotectants and potential contamination via liquid nitrogen contact associated with vitrification (Gosden, 2011; Wang et al., 2012) . To date, there have been only a limited number of single-centre studies using single-centre data to investigate the perinatal outcomes of births following vitrification of blastocysts when compared with the slow freezing method and appropriate fresh controls (Stehlik et al., 2005; Takahashi et al., 2005; Wikland et al., 2010; Feng et al., 2012 ).
Our population-based study was designed to determine the clinical efficacy of vitrification of blastocysts compared with fresh blastocyst transfer and slow freezing methods and the associated perinatal outcomes of births following transfer of fresh, slow frozen and vitrified blastocysts.
Materials and Methods

Data
A population-based cohort of autologous fresh and thaw cycles performed between January 2009 and December 2011 in Australia and New Zealand was evaluated retrospectively. ART treatment information and perinatal outcomes following fresh, slow frozen and vitrified blastocyst transfer cycles were obtained from the Australian and New Zealand Assisted Reproduction Database (ANZARD). Data for ANZARD are collected annually from all fertility centres within Australia and New Zealand to monitor the perinatal outcomes of births following ART treatments and to access the effectiveness of ART treatments.
Between January 2009 and December 2011, there were 177 813 autologous fresh and thaw cycles performed in Australia and New Zealand. Of the autologous cycles, blastocyst transfers made up 50% of fresh cycles and 60% of initiated thaw cycles (a cycle where embryos were thawed with intention to transfer). Mixed fresh/thawed embryo transfer cycles (0.1%), mixed slow freezing/vitrified embryo transfer cycles (0.3%), mixed cleavage/ blastocyst embryo transfer cycles (0.2%) and fresh cycles with no embryo transferred (7.7%) were excluded. A total of 46 890 fresh blastocyst transfer cycles, 12 852 initiated slow frozen blastocyst thaw cycles and 20 887 initiated vitrified blastocyst warming cycles were included in the data analysis.
Study factors and outcome measurements
In cycles with transfer of fresh blastocysts, maternal age was calculated in completed years of age at treatment, i.e. by subtracting the mother's date of birth from the datewhere the stimulation drug was administrated for stimulated cycles or the date of the last menstrual period for natural fresh cycles. In thaw cycles with transfer of slow frozen or vitrified blastocysts, maternal age was calculated in completed years of age at embryo freezing, i.e. by subtracting the mother's date of birth from the freezing date of the thawed embryos. Cause of infertility was classified as: male factor only infertility, female factor only infertility, combined male-female factor infertility, and unexplained infertility where neither a male nor female factor problem was diagnosed.
Clinical pregnancy was defined as a pregnancy that met at least one of the following criteria: known to be ongoing at 20 weeks; evidence by ultrasound of an intrauterine sac with or without a fetal heart; examination of products of conception revealing chorionic villi; or a definite ectopic pregnancy that has been diagnosed laparoscopically or by ultrasound. Births were defined as live births or stillbirths of ≥20 weeks gestation or ≥400 g birthweight. A live delivery was defined as the delivery of one or more live born infants, with the birth of twins or higher order multiples counted as one live delivery. Low birthweight was defined as weight at birth ,2500 g. For singletons, small for gestational age (SGA) was defined as a birthweight below the 10th percentile for the gestational age and large for gestational age (LGA) was defined as a birthweight greater than the 90th percentile for gestational age Outcomes following vitrification or slow freezing of the Australian population norm (Dobbins 2012) . Gestational week was calculated in completed weeks based on the embryo transfer date and baby's date of birth. Preterm birth was defined as birth before 37 completed weeks of gestation. Perinatal deaths included fetal deaths of at least 400 g birthweight or 20 weeks gestation and neonatal deaths occurred within 28 days after birth.
Statistical analysis
Pairwise comparisons were made between the vitrified blastocyst group and slow frozen or fresh blastocyst group. A Chi-square test was used for categorical variables and t-test was used for continuous variables. Cox regression was used to examine the pregnancy outcomes (clinical pregnancy rate, miscarriage rate and live delivery rate) and perinatal outcomes (preterm delivery, low birthweight births, SGA and LGA births, and perinatal mortality) following transfer of fresh, slow frozen and vitrified blastocysts. Adjusted relative risk (ARR) and 95% confidence intervals (95% CI) were calculated. Adjustment was made for maternal age, cause of infertility, parity, duration of embryo storage, number of embryos thawed/transferred and method of fertilization. Findings with a P-value ,0.05 or a CI not including 1 was considered statistically significant. All statistical analysis was performed using SPSS 20.0 software (Armonk, NY, USA: IBM Corp.).
Ethical approval
Ethics approval for this study was granted by the Human Research Ethics Committee of the University of New South Wales, Australia.
Results
Between 2009 and 2011, there were 46 890 fresh blastocyst transfer cycles and 33 739 initiated thaw blastocyst cycles (12 852 slow freezing and 20 887 vitrification cycles). Table I presents the maternal demographic and obstetric characteristics in the fresh, slow frozen and vitrified blastocyst groups. The mean maternal age was 35.2 + 4.7 years for the fresh group, 33.6 + 4.4 years for the slow freezing group and 34.2 + 4.4 years for the vitrification group (Table I) . The difference of mean maternal age between fresh group and vitrification group was 1.0 years (95% CI for the difference 0.96 -1.04). Similarly the difference of mean maternal age between vitrification group and slow freezing group was 0.6 years (95% CI for the difference 0.55 -0.65). Due to the large sample size, all differences between the fresh, slow freezing and vitrification group were highly significant (P , 0.001) ( Table I) .
95.6% of the initiated vitrified blastocyst warming cycles resulted in embryo transfer, which was significantly higher than the 90.6% in the slow freezing group (ARR: 1.05, 95% CI: 1.03 -1.08, P , 0.001) (Tables II and IV ). On average, 1.3 + 0.6 vitrified blastocysts were warmed per cycle, while 1.5 + 0.8 slow frozen blastocysts were thawed per cycle. A higher proportion of single embryo transfer was reported in the vitrification group (88.6%), compared with 83.8% in the slow freezing group and 75% in the fresh group (Table II) .
The 46 890 fresh blastocyst transfers, 11 644 slow frozen blastocyst transfers and 19 978 vitrified blastocyst transfers resulted in 16 845, 2766 and 6537 clinical pregnancies, which led to 13 049, 2065 and 4955 live deliveries, respectively (Table III) . The clinical pregnancy rate and live delivery rate per embryo transfer cycle were highest in the fresh blastocyst transfer group (35.9 and 27.8%, respectively) ( Table III) . The vitrified blastocyst group had a significantly higher clinical pregnancy rate per thaw cycle compared with the slow frozen blastocyst group (31.3 and 21.5%, respectively; ARR: 1.43, 95% CI: 1.37 -1.50) and clinical pregnancy rate per embryo transfer cycle (32.7 and 23.8%, respectively; ARR: 1.38, 95% CI: 1.32 -1.45) (Tables III and IV (Tables III and IV) . The perinatal outcomes of singletons following transfer of fresh, slow frozen and vitrified blastocysts are presented in Table V . The mean birthweight of singletons following vitrified blastocyst transfer (3421.6 + 590.5 g) was significantly heavier than that of singletons following fresh blastocyst transfers (3276.2 + 611.6 g) (P , 0.001) ( Table V) . A significantly lower proportion of low birthweight singletons was reported in the vitrified blastocyst group compared with the fresh blastocyst group (ARR: 0.67, 95% CI: 0.58 -0.78). Compared with singletons born after transfer of fresh blastocysts, the likelihood of SGA births was 40% lower for singletons born after transfer of vitrified blastocysts (ARR: 0.60, 95% CI: 0.53 -0.68), and 36% lower for singletons born after slow frozen blastocysts (ARR: 0.64, 95% CI: 0.53 -0.78). Both slow frozen and vitrified blastocyst transfer group resulted in higher risk of LGA births compared with the fresh blastocyst transfer group (ARR: 1.77, 95% CI: 1.57 -2.00, ARR: 1.54, 95% CI: 1.40 -1.69, respectively) ( Table VI) . The mean gestational age was comparable in singletons after transfer of fresh, slow frozen and vitrified blastocysts (38.4, 38.5 and 38.5 weeks, respectively) ( Table V) . The risk of preterm birth (,37 completed weeks of gestation) decreased among singletons in the vitrified blastocyst group compared with the fresh blastocyst group (ARR: 0.86, 95% CI: 0.77 -0.96) (Table VI) .
Discussion
This study provides evidence at a population level that vitrification of blastocysts can achieve a higher clinical pregnancy rate and live delivery rate with comparable perinatal outcomes to those following conventional slow freezing methods. This is the first country-level population-based study to investigate the clinical efficacy and perinatal outcomes following transfer of fresh, slow frozen and vitrified blastocysts.
Compared with slow frozen blastocyst transfer cycles, vitrified blastocyst transfer cycles resulted in an almost 50% higher clinical pregnancy rate and 40% higher live delivery rate. Previous single-centre studies have reported comparable if not better clinical pregnancy rates of transfer of vitrified blastocysts than those obtained in slow frozen blastocyst transfer cycles. A retrospective US study found that the pregnancy rates of vitrified Day 5 blastocysts are significantly increased relative to slow frozen Day 5 blastocysts (Stehlik et al., 2005) . A meta-analysis based on four randomized controlled trials (RCTs) of both cleavage stage embryos and blastocysts found a significantly higher clinical pregnancy rate (89/230 versus 128/387; odds ratio (OR): 1.55, 95% CI: 1.05 -2.32) with vitrification compared with slow freezing, but no statistically significant difference in the clinical pregnancy rate was found between vitrification and slow freezing in sub-analyses for cleavage stage embryos (OR: 2.22, 95% CI: 0.91 -5.43) and blastocysts (OR: 1.32, 95% CI: 0.81 -2.17) (AbdelHafez et al., 2010). Significantly higher pregnancy rates, delivery rates and implantation rates were reported with vitrification compared with slow freezing for both cleavage stage embryos and blastocysts (Wong and Wong, 2011) .
The results of this study showed that compared with singletons born after transfer of fresh blastocysts, singletons born after transfer of vitrified blastocysts were at 14% less risk of being born preterm (ARR: 0.86, 95% CI: 0.77 -0.96), 33% less risk of being low birthweight (ARR: 0.67, 95% CI: 0.58 -0.78) and 40% less risk of being SGA (ARR: 0.60, 95% CI: 0.53 -0.68). Cohort studies of comparison between perinatal outcomes after fresh blastocyst transfers and vitrification of blastocysts are relatively rare. Wikland and colleagues reported significantly higher median birthweight (adjusted P-value ¼ 0.0362) and lower proportion of SGA (adjusted P-value ¼ 0.0085) among singletons born after transfer of vitrified blastocysts compared with those of the fresh blastocysts group after adjusting for maternal BMI and parity (Wikland et al., 2010) . No significant difference was found for the rate of preterm births between the fresh and vitrified blastocysts group in the Wikland study. This was probably attributable to the small number of preterm births with only nine preterm births reported in the fresh blastocyst group and seven reported in the vitrified blastocyst group. A recent study of 604 fresh blastocyst transfer cycles and 384 vitrified blastocyst transfer cycles found that babies in the vitrified group were heavier than those in fresh group (mean birthweight 3155.35 + 590.09 g and 3103.81 + 515.55 g, respectively) but no statistically significant difference was detected (Feng et al., 2012) . A 4-year follow-up study of perinatal outcome following vitrified blastocyst transfer found no statistical differences between neonates born after fresh and vitrified blastocyst transfer for birthweight and gestational age (Takahashi et al., 2005) . As the Takahashi study did not distinguish the perinatal outcomes of singletons from multiple births, the difference between their findings and those in our study could partially be explained by the multiple birth rate of 32.9%.
Compared with singletons following fresh blastocyst transfer, the likelihood of low birthweight births and SGA births were significantly lower for singletons following transfer of both slow frozen and vitrified blastocysts. This finding is consistent with previous studies that have demonstrated decreased risk of low birthweight and SGA births following cryopreserved cycles (Pelkonen et al., 2010; Sazonova et al., 2012) and suggests that this phenomenon is related to the nature of cryopreserved cycles rather than the method of cryopreservation (slow freezing or LGA, n (%)* 1228 ( (Pelkonen et al., 2010) . Similarly, Sazonova and colleagues found a lower rate of low birthweight births among singletons following cryopreserved cycles when compared with singletons following fresh cycles (Sazonova et al., 2012) . Our study found the risk of being LGA increased among singletons following transfer of slow frozen (ARR: 1.77, 95% CI: 1.57 -2.00) and vitrified (ARR: 1.54, 95% CI: 1.40 -1.69) blastocysts. The underlying mechanism of decreased risk of low birthweight and SGA births, and increased risk of LGA births following transfer of slow frozen and vitrified blastocyst is not yet known and further studies are required to evaluate the long-term consequences.
In the present study, the clinical pregnancy rate and live delivery rate following transfer of vitrified blastocysts were lower compared with fresh blastocyst transfer cycles. This may be because, in clinical settings, slow freezing or vitrification will usually be carried out following the selection of the 'best' embryo(s) for fresh transfer. Therefore, the cryopreserved embryos are on average of poorer quality and correction for quality of embryos is required for comparisons of outcomes from fresh and thaw cycles (Edgar and Gook, 2012) . Recent studies reported similar clinical outcomes from transfer of vitrified blastocysts compared with those of fresh blastocyst transfer cycles when similar quality of blastocysts were transferred (Zhu et al., 2011; Feng et al., 2012) . Feng and colleagues found that fresh and vitrified single-blastocyst transfers yield similar clinical pregnancy rates (52.15 and 46.61%, respectively) when a similar cohort of blastocysts graded ≥3BB was transferred (Feng et al., 2012) . Similarly, when good quality blastocysts were vitrified, significantly higher clinical pregnancy rate and implantation rate were reported in the vitrified group compared with the fresh group for women aged ,40 years undergoing blastocyst transfer cycles (Zhu et al., 2011) . A recent systematic review and meta-analysis showed that frozen embryo transfer results in significantly higher ongoing pregnancy rates and clinical pregnancy rates compared with fresh embryo transfer (Roque et al., 2013) . The improved pregnancy rate and perinatal outcomes seen after transfer of frozen embryos compared with transfer of fresh embryos maybe related to the adverse effects of ovarian hyperstimulation on endometrial receptivity in fresh cycles (Shapiro et al., 2011; Roque et al., 2013) . However, it should be noted that in clinical practice women with an excess of appropriate embryos available for cryopreservation would be expected to have better prognosis than women who have only one suitable good quality embryo available for a fresh cycle (Wang et al. 2010) . While majority of women returned for thaw cycles were not successful in their fresh cycles, women undergoing fresh cycles with an excess of embryos for cryopreservation are expected to have better prognosis than women undergoing thaw cycles. Future RCTs should be conducted to investigate whether an elective freeze all policy with vitrification can be considered as an alternative embryo transfer strategy to avoid the potentially poor endometrial receptivity or ovarian hyperstimulation syndrome in fresh cycles.
A major limitation of this population-based study is the lack of information available on clinical-specific cryopreservation protocols and processes for slow freezing-thaw and vitrification-warm of blastocysts and the potential impact on outcomes. The protocols for slow freezing-thaw and vitrification-warm of blastocysts may vary between clinics. The majority of blastocyst vitrification in Australia and New Zealand utilizes methodology involving high concentrations of both dimethyl sulphoxide (DMSO) and ethylene glycol (EG) together with a non-permeating cryoprotectant (sucrose or trehalose), while some clinics use a method in which the DMSO is replaced by propanediol (PROH) at a similar concentration. Currently, there is no consensus over which methods of vitrification and warming are optimal (Brison et al., 2012) . In addition, the quality of embryo transferred may differ across clinics where some clinics would only cryopreserve the top-quality embryos to maintain the implantation rate while other clinics might wish to keep the reproductive potential of relatively poorer quality embryos (Edgar and Gook, 2012) . The lack of consistent cryopreservation protocols and comparison of embryo qualities might over-estimate the successful rate of vitrification and underestimate the successful rate of slow freezing of blastocysts. That is, the higher clinical pregnancy rate and live delivery rate with vitrified blastocysts might be due to the possibility that the clinics with the higher fresh blastocyst implantation rates use vitrification while those with lower implantation rates use slow freezing, rather than the superiority of vitrification methodology. However, the successful rate of vitrified blastocyst transfer was consistently higher than those of slow frozen blastocysts across the study period, even though the use of vitrification increased significantly during this period. Vitrification was reported for 73.6% of autologous thaw cycles where a blastocyst was transferred in 2011, compared with 33. Macaldowie et al., 2013) . Another limitation of this study is that although this is the largest population-based study reported in this field, the data are observational and hence conclusions concerning the biological effects of vitrification and slow freezing cannot be drawn from our study. In addition, this study used each treatment cycle as the unit of analysis where one woman could be included in both fresh and thaw cycles. Future studies would investigate the clinical efficacy of and perinatal outcomes after transfer of fresh, slow freezing and vitrification of blastocysts by using each individual woman as the unit of analysis.
Conclusion
This study presents population-based evidence on clinical efficacy and perinatal outcomes after transfer of fresh, slow freezing and vitrification of blastocysts. Compared with slow freezing of blastocysts, vitrification of blastocysts resulted in significantly higher clinical pregnancy and live delivery rates with comparable perinatal outcomes at population level. At a policy level, the comparatively better perinatal outcomes associated with vitrified rather than fresh blastocysts demonstrated in this retrospective study provide further evidence for the use of vitrification-warm cycles as one of the strategies to optimize perinatal outcomes following ART treatment.
